Insulet (PODD) EBIT Growth (1y) (2011 - 2026)
Insulet (PODD) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.56% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 11.83% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 19.54% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 20.97% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 90.95% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -18.12% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 74.18% |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 37.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.50% |
| Dec 31, 2025 | 33.85% |
| Sep 30, 2025 | 33.60% |
| Jun 30, 2025 | 122.20% |
| Mar 31, 2025 | 56.06% |
| Dec 31, 2024 | 2.63% |
| Sep 30, 2024 | 60.77% |
| Jun 30, 2024 | 75.24% |
| Mar 31, 2024 | 105.42% |
| Dec 31, 2023 | 353.19% |
| Sep 30, 2023 | 1,789.66% |
| Jun 30, 2023 | 216.48% |
| Mar 31, 2023 | -26.91% |
| Dec 31, 2022 | -52.72% |
| Sep 30, 2022 | -91.39% |
| Jun 30, 2022 | -201.52% |
| Mar 31, 2022 | 132.52% |
| Dec 31, 2021 | 780.82% |
| Sep 30, 2021 | 41.60% |
| Jun 30, 2021 | -4.36% |